Aimmune Therapeutics (NASDAQ:AIMT) issued its earnings results on Thursday. The biotechnology company reported ($0.89) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.03, Briefing.com reports.
Shares of AIMT stock opened at $30.29 on Friday. The company has a market cap of $1.88 billion, a P/E ratio of -11.61 and a beta of -0.10. Aimmune Therapeutics has a 52-week low of $24.56 and a 52-week high of $42.00.
A number of equities analysts have recently commented on AIMT shares. ValuEngine lowered shares of Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 7th. Cantor Fitzgerald set a $62.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 15th. BidaskClub lowered shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Stifel Nicolaus started coverage on shares of Aimmune Therapeutics in a research report on Thursday, September 13th. They set a “hold” rating and a $33.00 target price on the stock. Finally, Roth Capital set a $80.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 9th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $50.70.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Read More: Diversification
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.